Navigation Links
GPhA Praises President Obama's Support for Safe and Affordable Biogenerics as Critical Solution to America's Ailing Health Care System

ARLINGTON, Va., Feb. 26 /PRNewswire/ -- The Generic Pharmaceutical Association (GPhA) today applauded President Obama's budget proposal for including a workable approval pathway for biogenerics that will substantially reduce health care costs by increasing access to quality care at affordable prices. The President's budget proposal would ensure that this process mirrors the proven Hatch-Waxman market exclusivity model, by ensuring that brand companies cannot extend exclusivity using "ever-greening."

"For patients across the country suffering from cancer, diabetes and other diseases, the support stated by President Obama today for a workable biogenerics approval pathway is lifesaving news. With countless patients struggling to pay the high costs of brand biopharmaceuticals, an approval pathway for safe, effective and affordable biogeneric medicines that provides access sooner rather than later is desperately needed. GPhA applauds the President's budget message specifically stating that a workable scientific, regulatory and legal pathway with exclusivity provisions consistent with the Hatch-Waxman model must be enacted. The exclusivity provisions of Hatch-Waxman have been a successful model, fostering innovation and competition while saving hundreds of billions of dollars, and this same success can be achieved with biogenerics," stated GPhA President and CEO Kathleen Jaeger.

"GPhA, AARP and numerous employers, labor, consumer and other organizations have consistently called for the creation of a workable approval pathway for biogenerics. We are pleased that the budget proposal specifically calls for: (1) creation of such a pathway; (2) biologic market exclusivity incentives consistent with 'the principles in the Hatch-Waxman law for traditional products;' and (3)'brand biologic manufacturers would be prohibited from reformulating existing products into new products to restart the exclusivity process, a process known as ever-greening.' The President clearly recognizes that unprecedented and unwarranted ever-greening provisions will only delay patient access to needed medicines and do nothing to lower health care costs.

"Controlling health care costs is a key component of the President's health care reform agenda and a critical step to putting our economy back on track. It is anticipated that by 2012, nearly half of all prescription drugs in the United States will be biologic products. As our elected officials grapple with serious economic and health care challenges, increasing access to generic and biogeneric medicines will significantly reduce health care costs and strengthen the availability of high quality health care," Jaeger concluded.

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Generics represent 67% of the total prescriptions dispensed in the United States, but only 20% of all dollars spent on prescription drugs. For more information about the industry, visit

SOURCE The Generic Pharmaceutical Association (GPhA)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AHIP Praises Bipartisan Senate Vote on Mental Health Parity
2. Union President Praises Hillary Clintons Health Plan
3. AIDS Action Council Praises Release of Latest State of AIDS in Black America Report
4. Lung Cancer Alliance Praises Congressional Call for Increased Commitment to Fund Lung Cancer Research
5. Bishops Conference Praises Senate Introduction of Pregnant Women Support Act
6. American Life League Praises Colorado Efforts to Stop Planned Parenthood Abortion Facility
7. Alliance for Quality Nursing Home Care Praises CMS Release of Updated Special Focus Facilities (SFF) List
8. Blunt Praises Presidents Plan to Save Medicare
9. FRC Action Praises John McCains Pro-Life Comments
10. Consumer Watchdog Praises CA HMO Regulators Promise to Reinstate Health Coverage for Wrongfully Cancelled Patients; Cautions That All Health Costs During Gap Must be Covered
11. USCCB Official Praises Senate Passage of Genetic Information Nondiscrimination Act
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in ... that delves into an array of issues that are presently affecting Americans. Dedicated to ... dialogue, this show is changing the subjects consumers focus on, one episode at a ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to announce ... (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored to ... of twelve colleges and universities in the state of California make the cut. CBD ...
(Date:11/27/2015)... ... November 27, 2015 , ... Avid collector, Andrew Hawley ... Michigan boxing style concert posters. This is one of Joplin's most famous and beautiful ... at the University of Michigan in Ann Arbor. The According to Hawley, "It is ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think ... customers choose to buy during the Black Friday and Cyber Monday massage chair ... to search the Internet high and low to find the best massage chair deals, ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... to discuss bioavailability and the need to integrate dose form selection in early ... with OBN, the membership organization supporting and bringing together the UK’s emerging life ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 --> ... potential att använda SyMRI för att hitta ... patienter med multipel skleros (MS) eller hjärntumörmetastaser ... AB för att kunna använda SyMRI Research ... SyMRI kan man generera flera konstrastbilder från ...
(Date:11/26/2015)... , November 26, 2015 ... --> adds "Global Repaglinide ... "Investigation Report on China Repaglinide Market, ... forecasts data and information to its ... . --> ...
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
Breaking Medicine Technology: